Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor 
receptor (EGFR) gene in non-small cell lung cancers are associated with 
increased sensitivity of these cancers to drugs that inhibit EGFR kinase 
activity such as gefitinib and erlotinib. Responses to TK inhibitors in the 
absence of EGFR gene mutation for BAC patients have not been reported. A case of 
a patient with BAC refractory to chemotherapy who responded to gefitinib in the 
absence of EGFR gene mutations is reported. Tyrosine kinase inhibitors may have 
a role in BAC in the absence of EGFR gene mutations. Additional studies on other 
molecular alterations of the EGFR family members are needed to better predict 
response to these agents.